LIF and neoplasm: To evaluate the impact of chemo/anti-LIF/anti-PD-L1 on the tumor immune microenvironment, we followed the same experimental design as in Figure 1a and assessed the tumor-infiltrating immune cells using flow cytometry at day 15 post tumor implantation.